Futu News, December 13, this Monday $BIOHEART-B (02185.HK)$ The announcement was announced that it will issue 239.37 million shares from December 13 to 16. The company plans to issue 239.37 million shares, including a public sale of 2.394 million shares and an international sale of 21.543 million shares, with an issue price of HK$21.25-24.79 per share, and 500 shares per lot. It is expected to be listed on December 23.
The company issued shares in mid-November this year and was originally scheduled to go public on November 26, but on the eve of the listing, it was decided to delay the listing schedule and return the shares applied for the Hong Kong public sale.
Established in 2014, Baixinan is a leading innovative interventional cardiovascular device company in China. It focuses on fully degradable stents (BRS) and renal nerve block (RDN) treatments to address the unmet medical needs of Chinese patients in coronary and peripheral artery disease and hypertension.
As of the last practical date, the company has a core product and eight other pipeline products under development. The core product, BioHeart, is a self-developed BRS system used for percutaneous coronary intervention, and according to Frost & Sullivan's data, it is expected to become the world's first second-generation fully degradable stent system approved by regulation based on the results of multi-center randomized controlled clinical trials.
In terms of financial status, the company currently has no products approved for commercial sale, nor was it produced from product sales during the track record period...